Company Overview of Q Therapeutics, Inc.
Q Therapeutics, Inc., a clinical-stage company, engages in developing human cell-based therapies intended to treat neurodegenerative diseases of the brain and spinal cord. Its product candidate includes Q-Cells that are healthy human glial progenitor cells intended to restore or preserve normal activity of neurons by providing support functions that occur in healthy central nervous system (CNS) tissues. The company develops Q-Cells for application in a range of CNS diseases, including multiple sclerosis, transverse myelitis, cerebral palsy, and stroke, as well as other neurodegenerative diseases and injuries, such as amyotrophic lateral sclerosis, Huntington’s disease, spinal cord injury, st...
615 Arapeen Drive
Salt Lake City, UT 84108
Key Executives for Q Therapeutics, Inc.
President, CEO & Chairman of the Board
Scientific Co-Founder, Chief Strategy Officer & Chairman of the Scientific Advisory Board
Vice President of Research & Development
Compensation as of Fiscal Year 2018.
Q Therapeutics, Inc. Key Developments
Q Therapeutics, Inc. Announces Joint Venture With ReproCELL, Inc
Apr 23 18
Q Therapeutics, Inc. and REPROCELL Inc. announced the formation of MAGiQ Therapeutics, Inc., a Japanese joint venture company. MAGiQ will develop iPSC-derived, glial-restricted progenitor cells (GRPs), in collaboration with Q Therapeutics and REPROCELL, to treat demyelinating and degenerative diseases of the CNS. Under the leadership of Kuchiishi and Chief Scientific Officer Mahendra Rao MD, PhD, MAGiQ will first target the demyelinating disease transverse myelitis and the degenerative disease amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease). The iPSC-derived GRP cell (iGRP) product will be tested in proof-of-concept human trials, sponsored by REPROCELL, under the accelerated approval pathway permitted by Japan’s PMDA. This unique regulatory process, designed to move cell and gene therapies to human use more rapidly than in most countries, will enable clinical data and conditional product approval for application to regulatory filings worldwide. MAGiQ is a 50:50 joint venture, in which Q Therapeutics will contribute its patented technology to derive and manufacture glial-restricted progenitor (GRP) cells from any tissue source, including iPSC. REPROCELL will support manufacturing process development of iGRPs through to completion of proof-of-concept clinical trials in addition to providing integration-free, virus-free and clinically relevant human iPSC lines using proprietary RNA reprogramming technology. The clinical data will equip both MAGiQ and Q Therapeutics to bring the iGRP product to other indications and markets.
Q Therapeutics, Inc. Announces Research Collaboration with REPROCELL Inc
Dec 13 17
Q Therapeutics, Inc. announced a collaborative research agreement with REPROCELL Inc. that combines each company’s proprietary technologies to develop new iPS cell (IPSC) therapies for central nervous system (CNS) diseases. Q Therapeutics has patented a process to manufacture glial-restricted progenitor (GRP) cells from any tissue source. GRPs have been proven safe and effective in several pre-clinical CNS disease models. Q Therapeutics has obtained Investigational New Drug (IND) clearance from the FDA in Amyotrophic Lateral Sclerosis and Transverse Myelitis (both orphan indications) for its adult cell product, Q-CELLS™. REPROCELL has developed a proprietary process to manufacture integration-free, virus-free and clinically relevant human iPSC lines using proprietary RNA reprogramming technology. This process is suitable for manufacturing robust, consistent and high quality functional cells at commercial scale. Combining these technologies will enable rapid generation of therapeutic-grade, iPSC-derived GRPs to generate safety and efficacy data in preclinical disease models. Q Therapeutics’ expertise in obtaining regulatory approval in the United States and REPROCELL’s ongoing clinical partnerships in Japan enable them to work toward approval of IPSC-derived products on a global scale.
Q Therapeutics, Inc. Appoints Tom Parks as Independent Member to Its Board of Directors
Aug 7 17
Q Therapeutics, Inc. announced the appointment of Tom Parks, Ph.D. as an independent member to the Company's Board of Directors. In addition, Dr. Parks has agreed to serve on the Board's Nominating and Governance Committee; and will be joined on the Committee by current independent directors, Peter Barton Hutt, Peter Grebow, and Hunter Jackson. He currently serves on the boards of Navigen Pharmaceuticals Inc., SentrX Animal Care Inc., and ConusRx Inc.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|